IL-6 receptor monoanti-Kevzara, clinical failure of stage III for the treatment of the new coronavirus COVID-19

Sanofi and Regeneron announced that the stage III trial of the rheumatoid arthritis drug Kevzara (sarilumab) 400 mg failed to reach its primary secondary and end point in patients who need mechanical ventilationCOVID-19Based on the results??, clinical trials have been discontinued, including the second batch of patients receiving a higher dose of 800 mgKevzara is a monoantidrug that targets leukocyte interleukin-6 (IL-6) receptorsSanofi and Regeneron said that "small positive trends" were observed in the 400 mg dose group, but these were not statistically significant and were "negative offset" by "negative trends" in criticalpatients without intubationIn addition, 80 percent of Kevzara patients and 77 percent of placebo patients experienced adverse eventsIn patients treated with Kevzara, severe adverse events with a higher frequency included polyorgan insufficiency syndrome (6 percent of Kevzara and 5 percent for placebo) and low blood pressure (incidence 4 percent and 3 percent, respectively)Sanofi and Regeneron explained that the Kevzara trial was designed after a small one-arm study in China that found elevated IL-6 levels in COVID-19 patients who were mostly hospitalized with severe fever in China, and that using Roche's anti-IL-6 receptor monoanti-Actemra/Roactemrb (tocilizumab) was quickly reduced and improved for fever oxygen co-operationMarch, Roche conducted A Phase III clinical trialins in patients with severe COVID-19 pneumonia to assess the therapeutic potential of Actemra/RoActemra's combined standard careSubsequently, the company announced a partnership with Gilead Sciences to assess the combined therapeutic potential of Actemra/RoActemra and remdesivir